Home > Journals > Minerva Endocrinology > Past Issues > Articles online first > Minerva Endocrinology 2021 Apr 01

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Minerva Endocrinology 2021 Apr 01

DOI: 10.23736/S2724-6507.21.03378-2

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

FGF23 functions and disease

Cristiana CIPRIANI , Salvatore MINISOLA, Luciano COLANGELO, Viviana DE MARTINO, Federica FERRONE, Federica BIAMONTE, Vittoria DANESE, Chiara SONATO, Rachele SANTORI, Marco OCCHIUTO, Jessica PEPE

Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy


PDF


The main function of fibroblast growth factor 23 (FGF23) is the regulation of phosphate metabolism through its action on the sodium-dependent phosphate cotransporters in the proximal renal tubules. Additionally, FGF23 interacts with vitamin D and parathyroid hormone in a complex metabolic pathway whose detailed mechanisms are still not clear in human physiology and disease. More recently, research has also focused on the understanding of mechanisms of FGF23 action on organs and system other than the kidneys and bone, as well as on its interaction with other metabolic pathways. Collectively, the new evidence are successfully used for the clinical evaluation and management of FGF23-related disorders, for whom which new therapies with many potential applications are now available.


KEY WORDS: FGF23; Phosphate; Physiology; Pathophysiology

top of page